PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the best robotic surgery stocks to buy.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) received several rating updates following the release of its financial results for fiscal Q1
Piper Sandler lifted the price target on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) to $35 from $28 on April 30, maintaining an Overweight rating on the shares and noting that the company reported fiscal Q1 results that beat on the top-line and reiterated full-year guidance across all key metrics. The firm further stated that the quarter was marked by strong domestic capital placements with impressive all-time high ASPs, which resulted in the stock trading up more than 10% after hours. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) also received a rating update from Baird the same day, with the firm lifting the price target on the stock to $28 from $27 and maintaining a Neutral rating on the shares.
The firm stated that it updated its model after its fiscal Q1 beat results. However, it added that the long-term adoption trajectory is keeping them on the sidelines. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage surgical robotics company that develops transformative solutions for urology.